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Medical practitioners typically utilize the following protocol when advising pregnant women about
testing for the possibility of genetic disorders: Pregnant women over the age of 35 should be tested
for Down syndrome and other genetic disorders; for younger women, such tests are discouraged since
they can cause a miscarriage. The logic appears compelling. The rate at which amniocentesis causes
a miscarriage is constant while genetic disorders rise over a woman’s reproductive years. Hence the
potential benefit from testing – being able to terminate a fetus with a genetic disorder – rises with maternal
age. We argue that this logic is incomplete. While the benefits to testing rise with age, so do the costs.
While undergoing an amniocentesis always entails the risk of miscarriage of a healthy fetus, these
costs are lower at early ages, because there is a higher probability of being able to replace a miscarried
fetus with a healthy birth at a later age. We develop and calibrate a dynamic model of amniocentesis
choice to explore this tradeoff. For parameters that characterize realistic age patterns of chromosomal
abnormalities, fertility rates and miscarriages following amniocentesis, our model implies a falling,

















1.  Introduction 
  Amniocentesis and chorionic villus sampling (CVS) are methods of diagnosing Downs 
Syndrome and other genetic disorders. Amniocentesis and transabdominal CVS involve inserting 
a thin hollow needle through a pregnant woman’s abdomen to remove fetal cells from the 
amniotic sac (amniocentesis) or from around the chorionic villi (CVS).
1 Microscopic 
examination of the chromosome size and banding patterns of these fetal cells allows medical 
laboratories to identify and arrange each of the 24 different chromosomes (22 pairs of autosomes 
and one pair of sex chromosomes) (a karyotype), which then serves as a tool in the diagnosis of 
genetic diseases. An extra copy of chromosome 21 in a karyotype identifies Down syndrome the 
most common genetic disorder (National Center for Health Statistics, 1994). 
  Children with Down syndrome suffer from general hypotonia (poor muscle strength and 
elasticity), mental retardation, growth retardation, and are at significant risk for congenital 
malformations of which heart problems are the most common. While some therapies are 
available for specific malformations there are no proven therapies available to treat the cognitive 
problems associated with Down syndrome (Dick, et al., 1996). In developing countries, life 
expectancy for children with Down syndrome is approximately 35 years (Brazil) but advances in 
medical treatment for specific conditions has increased life-expectancy in the U.S. to 
approximately 55 years.
2 The lifetime economic cost of Down syndrome is estimated at 
$410,000 per child based on U.S. cross-sectional data from 1988 (Waitzman, Romano & 
Scheffler, 1994). This of course greatly underestimates the full cost to families which include 
                                                 
1 Transcervical CVS involves inserting a thin tube through a woman’s vagina and cervix to the villi, and using 
suction to remove a small sample of fetal cells. The risks involved in transcervical and transabdominal CVS are the 
same and equally prevalent. For a concise discussion of CVS methods and risks, see  
http://www.modimes.org/HealthLibrary2/factsheets/ChorionicVillusSampling.htm,. 
2 For life expectancy for those born with Down syndrome in Brazil see 
http://www.epub.org.br/cm/n04/doenca/down/down_i.htm and for the U.S. see 
http://www.ndss.org/aboutds/aboutds.html.   2
maternal depression and difficulties with marital and sibling relationships (Dick, et al., 1996). 
Down syndrome accounts for about half of chromosomal abnormalities detected by karyotyping. 
Spina bifida (an incompletely enclosed spinal cord) and anencephaly (the absence of a large part 
of the brain and skull) are two less common but more fatal genetic disorders detected by 
amniocentesis and CVS. 
  Both CVS and amniocentesis provide very accurate diagnosis of Down syndrome in a 
fetus, greater than 99%. However, both have important risks that a pregnant woman must 
consider. The amniocentesis procedure results in a spontaneous miscarriage for 1 in 100 to 1 in 
200 women and the CVS procedure carries an even greater risk of procedure-related fetal loss 
(between 1% and 1.5%).
3 And while the fraction of pregnancies afflicted with Down syndrome 
and other genetic disorders rises with maternal age, even at age 49 the vast majority of 
pregnancies will prove to be chromosomally normal. What this means is that when 
amniocentesis induces the loss of a fetus, the mother almost always looses a fetus that would 
have developed into a healthy child. 
  The current standard in obstetric practice is to recommend that women pregnant at age 35 
or older have an amniocentesis or CVS but this is not recommended for pregnant women prior to 
that age. The American College of Obstetricians and Gynecologists, the College of Medical 
Genetics and the Canadian Task Force on Periodic Health Examination all agree that a woman 
who is pregnant and is 35 years old or older should be tested using either amniocentesis or CVS. 
The recommendations for women who are pregnant and younger than age 35 varies, but 
generally either the “triple marker” test or no test at all is recommended.
4 Using age 35 as an age 
                                                 
3 See U.S. Preventative Service Task Force. (1996). The CVS procedure is feasible to perform earlier in a pregnancy 
than is amniocentesis. 
4 The “triple marker” test is a screen of a pregnant woman’s blood for particular proteins and is an alternative to 
amniocentesis and CVS. While this test carries lower medical risks, it is far less accurate and typically it detects only   3
to start testing is based on a compelling, but we argue, incomplete logic. Figure 1 graphs the 
estimated number of fetuses afflicted with a chromosomal abnormality per 100,000 pregnancies 
by maternal age. Figure 1 also displays an upper and lower bound estimate on the number of 
fetuses lost for every 100,000 amniocenteses performed. It is clear that prior to ages 35-38 more 
healthy fetuses would be lost from performing amniocentesis on all women than would be the 
number of chromosomally abnormal fetuses detected. It is further argued that, after age 35-38, 
when chromosomal abnormalities rise rapidly, the rate of successful detection of rate 
chromosomal abnormal fetuses via amniocenteses exceeds the incidence of miscarriages 
resulting from administering this procedure. It is the latter claim (and accompanying evidence) 
that has led the medical profession to adopt age 35 as the threshold age for recommending 
genetic testing to patients. 
Figure 1 here 
  Economists have criticized this threshold-age approach. For example, Sicherman, 
Bombard and Rappoport (1995) (SBR hereafter) point out that this approach makes sense from 
an expected utility theory viewpoint only if the utility loss from a miscarriage due to having an 
amniocentesis equals the utility gain from avoiding bearing and raising a Down syndrome child. 
Clearly, women (parents) may differ with respect to how they value the “pain and loss” 
associated with miscarrying a fetus, on terminating a pregnancy through abortion, and on how 
they value having additional children, including the relative utility gained from a healthy child 
versus one born with a chromosomal abnormality. SBR argue that a woman’s individual costs 
and benefits of each outcome can be combined with the probabilities of those outcomes to better 
aid women in their choice. 
                                                                                                                                                             
60% of Down syndrome fetuses. Some doctors will perform amniocentesis on women who test positive on the 
“triple marker” test. Because of the extremely high false positive rate others will not use the test at all.   4
  Like SBR, this paper relies on an expected utility approach but differs from SBR in an 
important way. While SBR set the expected utility model in a static context, our paper 
concentrates on the dynamic decisions inherent in family planning. Specifically, we model a 
woman’s choice about amniocentesis for a particular pregnancy within her lifetime choices over 
the quantity and quality of children. 
  There is a long tradition in demography that recognizes the importance of the outcomes 
for one child or one pregnancy on future choices about childbearing. For example, demographers 
have extensively studied changes in fertility in response to infant mortality, especially in 
developing countries (Shultz, 1969, 1976; Ben-Porath, 1976; Preston, 1978; Sah, 1991; Wolpin, 
1997). In our model, a procedure-induced miscarriage is viewed as in utero “infant mortality” 
but women can partially control this risk by their decisions of whether or not to have an 
amniocentesis. In particular, by not undergoing an amniocentesis, a woman can limit the risk of 
this form of infant mortality. At the same time, by not having an amniocentesis, she increases her 
chances of bearing a child with Down syndrome or another genetic disorder. In making her 
genetic-testing choice, a woman is always cognizant that she can replace a miscarried fetus, with 
some probability, at later ages. However, this option decreases as a woman approaches 
menopause. As a result, the “cost” of an amniocentesis rises with maternal age. This is the key 
different between our model and static expected utility models. In particular, the static model of 
SBR implies that women will always have a rising propensity to choose to undergo an 
amniocentesis because of her desire to avoid having a child born with a genetic disorder. In our 
dynamic model, this propensity may or may not rise with maternal age, precisely because women 
must balance the benefits associated with having an amniocentesis (avoiding having a child with 
a genetic disorder) with the costs of such procedures (running the risk of a procedure-induced   5
miscarriage of a healthy fetus). 
  The remainder of this article is organized as follows. Section 2 lays out a dynamic model 
of amniocentesis. We show that if the rate of Down syndrome were constant over maternal age, 
it would be optimal, in the sense of maximizing expected utility, for women to elect an 
amniocentesis at younger ages rather than at older ages. Since genetic disorders do rise with 
maternal age, this result makes clear that how the optimal choice changes with maternal age will 
depend on the rate of increase in genetic disorders relative to the rate of decrease in the 
probability of replacing a child lost by a procedure-induced amniocentesis. After laying out how 
the rates of amniocentesis vary by age and birth parity in U.S. data in Section 3, we then solve 
more realistic models, using numerical methods and plausible parameter values, to determine 
what the age pattern of amniocentesis choice might look like under reasonable biological 
parameters. The results of these simulations are presented in Section 4. Some implications of our 
simple model are strongly rejected by the data. For example, the data shows a clear jump in 
amniocentesis rates at age 35, the age threshold used by medical practitioners. However, other 
implications of the model are consistent with the data in Section 3, including: (a) a decline in 
amniocentesis rates as women approach the end of their reproductive years, (b) a higher rate of 
amniocentesis for lower parity children at most maternal ages, and (c) a larger drop in 
amniocentesis rates for lower parity children as a woman reaches menopause. Section 5 provides 
concluding observations. 
2.  Modeling Amniocentesis Choice 
2.1  The Elements of a Dynamic Model  
  Consider a model in which women, at each age t, t = 1,…,T, become pregnant. We treat 
pregnancies as biologically (and exogenously) determined, occurring with probability pt, 0 < pt <   6
1. Age T+1 is the age of menopause, after which woman’s probability of conception is zero (i.e., 
pT+1   0). Pregnant women confront three sequential choices at each age at which they are 
fecund. First, a pregnant woman may choose to abort the fetus, prior to any genetic testing. Let 
this choice be denoted by 
A
t C , where 
A
t C  is either equal to Abort or ~Abort. Second, conditional 
on not choosing to initially abort her pregnancy, a woman chooses whether or not to have a test, 
, for a genetic disorder, i.e., an amniocentesis. Let this choice be denoted by 
~A
t C




is either equal to Amnio or ~Amnio. We assume that the outcome on an amniocentesis ( = + or -) 
is always accurate. Third, conditional on not initially aborting and having a positive test, women 
choose whether or not to abort the fetus. Let    &~ AA
t C
  denote this choice, where    &~ AA
t C
  is 
either equal to Abort or ~Abort. Those women who do choose to have an amniocentesis, 
~A
t C
  = 
Amnio, may experience a (spontaneous) miscarriage, with probability m, 0 < m < 1. If the mother 
chooses not to undergo an amniocentesis, the pregnancy will end in a normal birth with 
probability q and a birth with a genetic disorder with probability (1-q). If she undergoes the 
procedure, the result of the test will be negative (no genetic abnormalities) or positive with the 
same probabilities (q and 1-q). The probability of a genetic disorder, (1-q), varies with the 
woman’s age. 
  The above set of actions and probabilistically-occurring events result in a set of potential 
outcomes at each age. In particular, women may have: a normal birth at age t, denoted by nt = 1; 
a birth with a genetic disorder (Down syndrome), denoted by dt = 1; a miscarriage, denoted by mt 
= 1; an abortion, denoted by at = 1; or no pregnancy, which is (implicitly) recorded by nt = dt = 
mt = at = 0. Let the cumulative values, or “stocks,” of these outcomes as of age t be denoted as Xt 
= Xt-1 + xt, where X = N, D, M, and A correspond to the outcomes x = n, d, m, and a.   7
  An essential feature of our model is that children, regardless of their type, are enduring 
goods. Furthermore, a couple’s other choices may have long run consequences. As such, we 
assume that parent’s instantaneous utility, ut, is a function of the accumulated choices and 
outcomes. Furthermore, couples will differ on the utility value of each of these. For example, 
some couples may get as much utility from a Down child as a healthy child, and other couples 
(women) may face a large utility cost of abortion while other women face none. These 
differences in tastes are known to a couple but are unknown to the econometrician. We model 
the instantaneous utility function as the sum of the utilities derived over the accumulation of each 
pregnancy event. That is,
5 
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u   
 
   , (1) 
where i = Present Discounted Disutility of the i
th abortion; 
D
i   = Present Discounted Utility of 
the i
th Down child; 
N
i   = Present Discounted Utility of the i
th healthy child; and i = Present 
Discounted Disutility of the i
th miscarriage. For example, the first healthy child will bring utility 
1
N   for every age after conception. Even though a woman can only conceive between t=1 and 
t=T, we assume that a woman will enjoy the utility from a child forever.
6 
  We assume a couple (woman) will make their (her) decisions between t=1 and t=T, 
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 .  
                                                 
5 This specification of the utility function is quite general. We do not require that gains and losses have a symmetric 
effect on parents’ (mother’s) utility. In particular, our specification can allow for forms of loss aversion. 
6 More generally, we only require that all fertility-related events of the same type (healthy, Down, abortion or 
miscarriage) generate a flow of utility for the same number of periods, regardless of the age at which they were 
experienced. For example, children can be enjoyed for many years, whereas the effect of abortions and miscarriages 
could last for only a few periods.   8
The additive separability of the utility function allows us to express the dynamic programming 
problem in terms of the Present Discounted Utility (PDU) that will be enjoyed over the lifetime 
from a particular event. That way, at each age, a woman’s contemporaneous utility is defined by 
the decisions she takes (which affect the probabilities of the different outcomes) and the PDU 
associated with each outcome (which depend on the state variables, Dt, Nt, Mt and At). 
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 (5) 
     
~& ~ ~ Pr 1 , , 1 ~ 1
AA A A AA
tt t t t t t m C C C C Abort C Amnio m
       , (6) 
where the operator, 1{x}, is equal to one if decision x is taken and 0 otherwise. (The structure of   9
the woman’s decision problem at age t is illustrated as a decision tree in Figure 2.) Notice that 
the probabilities are age dependent because some of the parameters, like the probability of 
having a child with Down syndrome (qt), are age dependent. We assume that 
D N
ii    , for all 
births, i.e., having a healthy child is always preferred to having a child with Down syndrome, 
and that  0 i    and  0 i   , for all births, i.e., abortions and miscarriages are never utility-
enhancing. 
Figure 2 here 
2.2  A Simplified Version of the Model 
  In this section, we consider a simplified version of this more general dynamic model to 
illustrate the sorts of implications that it can generate. Assume, for now, that a woman desires 
only one child. Assume that  1
N   = 1,  1
D    1, and 1 = 0, 1 = 0, i.e., an abortion or a miscarriage 
have no utility loss, a normal birth is normalized to a utility value of 1 and less utility is derived 
from Down syndrome child than a healthy child (but utility could be positive or negative). It 
follows that  ( 0, 0, , ) tt t t t uD N MA   = 0 prior to a woman’s first birth. At the time of a first 
birth, a woman’s utility is either  ( 0, 1, , ) tt t t t uD N MA    = 1, if the child is healthy, or 
(1 ,0 , , ) tt t t t uD N MA   =  1
D    1, if the child is born with Down syndrome. As the woman 
desires only one child, we can assume that after the birth of her child a woman receives her 
discounted utility payoff and then dies. If she does not have a child by age T (the age of 
menopause), her utility is zero. Finally, for now, we assume that m, q, and p do not vary with 
maternal age. While many of these simplifying assumptions are either unrealistic or factually 
inaccurate, they allow us to simplify a woman’s fertility decision-making problem. For example, 
it follows immediately from the above assumptions that in our simplified model we can abstract   10
from the choice of whether to abort a pregnancy prior to genetic testing (
A
t C  = Abort).
7 We 
consider the two remaining choices and describe how this simplified model can be solved 
recursively. 
Last Stage, Age T 
  Consider the last stage of the woman’s decision problem, at age T, after which she can no 
longer become pregnant. Figure 3 displays the decision tree for this age. We first consider the 
abortion decision, given a positive outcome on an amniocentesis (
&~ AA
t C
 ) and then determine 
her optimal amniocentesis decision rule.  
  Figure 3 here 
If a woman has had an amniocentesis, avoided a procedure-induced miscarriage and then tested 
positive for Down syndrome, the woman will abort the pregnancy if the value of a Down 
syndrome child is negative, since the only issue is whether a child afflicted with Down syndrome 
will produce positive utility to the woman. Thus, it follows that the optimal abortion choice at 
age T is characterized by the following decision rule: 
&~ 1
1
 if  0









     
  
. (7) 
Given a value of  1
D  , a woman will know whether she will abort should she be faced with 
a fetus with a genetic disorder and can make a choice at age T  on whether to undergo 
amniocentesis. If  1
D    0, we know that the woman will not abort. We also know she will not 
undergo an amniocentesis; doing so generates no present benefits (she will not abort if she tests 
positive) and entails the risk of miscarriage. In contrast, a woman with  1
D   < 0 would abort a 
                                                 
7 Since the choice to abort after genetic testing is available, and since abortion carries no disutility, a woman will 
never abort prior to genetic testing if 
N
i   > 0.   11
fetus if it tested positive for Down syndrome. It follows that the woman’s her expected utility is 
 
|& ~ ,, ( 1 )
AA
TT T E u pregnant C Amnio C Abort m q
      (8) 
if she undergoes an amniocentesis and 
  1 ,~ ( 1 )
D
TT E u pregnant C Amnio q q
      (9) 









   
, (10) 
which is that level of utility, as of age T, at which a woman is indifferent between having an 
amniocentesis and aborting if it tests positive and not having an amniocentesis. Thus, 
*
T   is the 
critical (utility) value that characterizes the optimal decision rule for a woman’s amniocentesis 
choice at age T:  
*
~ 1  if  ,











Note that it is possible that some women will decide to forgo an amniocentesis, even though 
having a Down syndrome child would reduce their utility, i.e.,  1
D   < 0. This could occur because 
while having an amniocentesis allow a woman to avoid having a Down syndrome child with 
certainty, having the test comes with the risk of losing a healthy child due to a miscarriage. 
  Before moving to age T-1, notice that the choice over amniocentesis only occurs among 
women pregnant at T. Therefore, as of age T-1, the payoffs at age T are expected to be 
 
*
11 (( 1) )
D D




1 (( 1 ) )
D
TT Eu pq m   ,   12
depending on the relationship between a woman’s utility from having a Down syndrome child, 
1
D  , and its critical value 
*
T   as of age T. 
Choices at Age T-1 
  Figure 4 displays the decision tree for a woman at her next-to-last fertile age, T-1. At this 
age, women still have choices they can make when they reach age T and these potential actions 




T     would have an 
amniocentesis and, hence, would abort a pregnancy that tested positive for a chromosomal 
abnormality. Because the costs of amniocentesis rise with age – while the benefits will not so 
long as q is constant – and the utility associated with not undergoing an amniocentesis is constant 
in this version of our model,












































Since a woman would undergo amniocentesis only if she would abort a fetus that tests positive 






  = ~Amnio  if  1







 and that 
*









        
. For all values of  1
D   in 
this range, it follows from (11) that a woman would not have amniocentesis at age T should she 
reach age T without a child and become pregnant at age T. Therefore, 
                                                 
8 Note that with more than one child, the (utility) costs of an amniocentesis will not be constant.   13
      
~
11 1 (1 ) (1 ) (1 ) (1 )
A DD
TT E u C Amnio mp q q m q q p q q
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A D
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qm m pm q p
qm p m q p
 
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          
 (13) 


















Given that the choice of amniocentesis occurs only among women pregnant at age T-1, it follows 
that the expected future utility as of age T-2 is given by one of the following three expressions, 
depending on a woman’s  1
D   relative to the critical values, 
*
T   and 
*
1 T   : 
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   
      
    
. (17) 
Figure 4 here   14
Choices at Age T-2 and Arbitrary Ages T-s 





T      would have an amniocentesis and hence abort a pregnancy that tested 
positive for a chromosomal abnormality. Again, because the costs of amniocentesis rise with age 

































T     , the abortion decision rule for women who test 
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                     
 

 . (19) 
Since a woman would undergo amniocentesis only when she would abort a fetus that tests 
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   
  
       
. For all  1
D   in this 
range, a woman would not have amniocentesis at any (fertile) age after T-s. Therefore,   15
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1 ~( 1 )
A D
Ts Ts Eu C A m n i o q q
      .  
Thus, the critical value for  1
D   for an arbitrary age T-s is given by 
 

* 1( 1 )









   
        
, (20) 
where   (1 )(1 ) 0 mm q     , and optimal decision-rule for a woman’s amniocentesis 
choice at that age is 
*
~ 1  if 













Predictions for the Simplified Model 
  What are the dynamic patterns of choices, especially with respect to amniocentesis, 
predicted by this simple model? Given the form of the decision rule for a woman’s 
amniocentesis choice at any age T-s in (21), how amniocentesis choice varies with maternal age 
depends upon how 
*
Ts    varies with age, given the single-crossing property of (21). Therefore, 
when s=0 (at age T), 
*






   
 and as tT   (as a woman approaches menarche), 
* 1 Ts    . That is, our simplified model implies that all young women would choose to undergo 
an amniocentesis and that the incidence of amniocenteses should decline monotonically with age. 
  Clearly, the above prediction with respect to how amniocentesis varies with maternal age 
is inconsistent with the advice given by the medical community. But how does it compare with 
the pattern for observed life cycle patterns of amniocenteses? To address this issue, and to   16
determine what features of our more general model of amniocentesis choice need to be modified 
to “fit the data,” we present, in the following section, evidence on the empirical relationship 
between amniocentesis and age. 
3.  Empirical Regularities on Amniocentesis and Maternal Age 
  To investigate the relationship between age and amniocentesis, we use data from the 
Detailed Natality Files (DNF) from the National Center for Health Statistics. The DNF include 
all births occurring within the United States. Beginning in 1988, for nearly every state, both 
congenital anomalies and a woman’s use of amniocenteses during pregnancy are recorded.
9 
While some twenty-two congenital anomalies are recorded, many are not genetic in origin.
10 In 
what follows, we concentrate on the data for three anomalies that are routinely discovered by 
amniocentesis: spina bifida, Down’s syndrome, and “other chromosomal anomalies.” These 
anomalies comprise more than half of all genetic disorders associated with newborns. 
  The benefit of the DNF is that it is a census of births in the U.S. and provides sufficient 
sample size to study choices of women pregnant at older ages. One potential issue is that this is a 
sample of live births only and hence Down’s syndrome fetuses that are aborted do not appear in 
the sample. However, it is possible to estimate the fraction of pregnancies for which 
amniocentesis is performed from the sample of live births. 
  From the DNF, we can obtain the following statistics: 
Birth
rt N  =   Total number of births of parity r occurring to women of age t; 
 
                                                 
9 The following states did not record amniocentesis on a significant percentage of State Birth Certificates (between 
1990 and 1994): Connecticut (16.6%), Maryland (20.4%) and Oklahoma (35.0%). The following states did not 
record at least one of the three abnormal conditions of the newborn on a significant percentage of State Birth 
Certificates: Rhode Island (20.08%), Connecticut (26.5%), Maryland (33.21%), Oklahoma (42.49%), New York 
(92.07%), and New Mexico (100%). 
10 These include central nervous, cardiac, musculoskeletal, and gastrointestinal.   17
& Birth Amnio
rt N  =  Total number of births of parity r preceded by an amniocentesis occurring 
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 , (22) 
where brt = 1 indicates a live birth of birth order r to a woman of age t. 
  For our purposes, we are interested in the rate of amniocentesis conditional on 
pregnancies and only on “relevant” pregnancies. In particular, an amniocentesis is not a relevant 
choice for a woman who would elect to abort a pregnancy, without regard to its genetic status, or 
for a woman who has a naturally occurring miscarriage prior to the amniocentesis choice.
11 We 
term relevant pregnancies as those that are wanted and viable and define them to include: (a) 
pregnancies ending in births that are not preceded by an amniocentesis (
&~ Birth Amnio
rt N ); (b) 
pregnancies resulting in births that are preceded by an amniocentesis (
& Birth Amnio
rt N ); (c) 
pregnancies followed by an amniocentesis that was positive and was aborted (
& Amnio Abort
rt N ); and 
(d) pregnancies followed by an amniocentesis that was negative but which induced a miscarriage 
(
& Amnio Miscarry
rt N ). It follows that the total number of wanted and viable pregnancies is equal to 
&~ & & &
&~
&~
(1 ) (1 )
W Birth Amnio Birth Amnio Amnio Abort Amnio Miscarry
rt rt rt rt rt
Birth Amnio Amnio Amnio Amnio
rt rt t rt t rt t
Birth Amnio Amnio
rt rt
NN N N N
NN q m N q N q m
NN
 
    

, (23) 
                                                 
11 There are a variety of estimates for the rate of fetal loss by gestational age. Taylor (1969) estimates the rate of loss 
(per 1000 pregnancies) by gestational age is approximately 28 (<7 weeks), 45 (8-11 weeks), 20 (12-15 weeks) and 
less than 10 after the 15
th week. Taylor’s estimates imply that 72% of miscarriages occur prior to week 16 of 
pregnancy. Amniocentesis is not performed prior to week 16.   18
where (1-qt) is the rate of chromosomal abnormalities at age t, m is the rate of miscarriage 
induced by the amniocentesis procedures, and 
Amnio
rt N  is the number of amniocentesis procedures 
performed. The substitutions of  (1 )
Amnio
rt t Nqm   for 
& Birth Amnio
rt N  and  (1 )
Amnio
rt t Nq   for 
& Abort Amnio
rt N  in the second line of (23) follow from invoking the following rational choice 
assumption: women who test positive for a chromosomal abnormality will always choose to 
abort their fetuses, while women who test negative will always choose to bring their fetuses to 
term. The DNF suggests that it is very rare that a woman give birth to a Down syndrome child 
after receiving amniocentesis.
12 Finally, we substitute 
Amnio
rt t Nq m  for 
& Amnio Miscarry
rt N  in (23) to 
reflect the fact that technical problems can cause an amniocentesis to end in a miscarriage at the 
rate m. 










 , (24) 
where Amniort is the indicator on whether a woman had an amniocentesis at age t for parity r and 
W
rt p  is an indicator that a pregnancy was wanted and viable. Recall that 
& Birth Amnio
rt N  = 
(1 )
Amnio
rt t Nqm  , or that 
Amnio
rt N  can be estimated as 
Amnio








.   Furthermore,  recall 
that 
W
rt N  = 
&~ Birth Amnio
rt N  + 
Amnio
rt N . It follows that that equation (24) can be expressed as 
                                                 
12 Among the live births that were reported to have Down syndrome between 1990 and 1994, 9.5% were preceded 

























, (25)   
where 
& Birth Amnio
rt N  and 
&~ Birth Amnio
rt N  are obtained from the DNF and we derive values for qt and m 
from medical studies. 
  Clearly, the rates in (25) may vary by more than just a woman’s parity (r) and age (t). For 
example, these rates may vary by her education or race. For example, because Down’s syndrome 
children are time intensive, one might expect that more educated women, who tend to have 
higher market-based opportunity costs of time, have higher rates of amniocentesis than less 
educated women. Further, more educated women may differ in the likelihood of becoming 
pregnant by birth parity and age, i.e., women having a first birth late in life are likely to have 
high levels of education. To deal such factors, one can calculate separate rates by these 
demographic characteristics. Alternatively, one can “hold constant” other covariates when 
calculating (25) by weighting one group to mimic the distribution of covariates of another. For 
example, we might standardize all of our age-specific estimates to the educational distribution 
for women who have a first birth at say age 21 in order to hold education constant across age. 
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 , and e indexes education groups.   20
  Figure 5 plots    Pr 1
W
rt rt Amnio p   for maternal ages 20 to 48 and for first through fourth 
parities. Several interesting patterns emerge from this Figure. First, regardless of parity, the rate 
of amniocentesis is near zero for women under the age of 35, but there is a steep rise in the rate 
of amniocentesis after that age for all parities. Second, the increase in rate of amniocentesis is 
larger the lower the parity of the child. Finally, while amniocentesis rates rise until a woman 
reach her mid-forties, they begin to decline after that age and they drop more precipitously for 
lower parities (first through third) than higher (fourth) parities. In particular, between the ages of 
46 to 48, the rate of amniocentesis drops from 31% to 20% for first births, from 28% to 14% for 
second births, and from 45% to 23% for third births. In contrast, there is very little decline in the 
corresponding rates for fourth births over this same age range. 
Figure 5 here 
  These age and parity patterns in rates of amniocentesis may be the result of changes in 
the composition of women across these groups. As noted above, women having a first birth at 
age 20 are likely to be less educated than those having their first birth at age 40. One easy way to 
account for this compositional effect on these rates is to condition, non-parametrically, on the 
educational attainment of women. Figure 6 plots    Pr 1
W
rt rt Amnio p   for maternal ages 20 to 48 
and for first through fourth parities for women whose highest level of educational attainment was 
a high school diploma. What is clear is that the patterns described for all women persist although 
the differences in the rates at any age across parity are reduced. Figure 7 plots 
  Pr 1
W
rt rt Amnio p   when the distribution of race, marriage and education is held constant for 
all parities and for all ages at the distribution found for women having a second birth at age 35.
13 
                                                 
13 Blacks, Hispanic, Others and Whites make up 11.0%, 11.6%, 6.0% and 72.4% of this population respectively. 
High School dropouts, high school graduates, some college and college graduates make up 14.4%, 26.6%, 22.7%,   21
Again, for the first through third children, the patterns remain. 
Figure 6 here 
Figure 7 here 
  In summary, the data on the rate of amniocentesis in Figures 5 through 7 display the 
following patterns: 
  Almost no women undergo an amniocentesis prior to age 35. 
  The rate at which women undergo the procedure rises rapidly after age 35, rising more the 
lower the child parity. 
  At every parity, the rate of amniocentesis declines as a woman approaches the end of her 
reproductive years. 
Presumably, the first and second of these patterns are heavily influenced by the “rules” that 
health care providers and insurance companies follow with respect to what ages they advise 
women to have an amniocentesis and the age-related restrictions that health care providers and 
insurers place on the reimbursements of this procedure that were noted in the Introduction. But it 
is less clear how to account for the third pattern, namely, that the incidence of amniocenteses by 
birth parity decline towards the end of woman’s reproductive lives. 
  As we already have seen, a simple version of a life cycle model of optimal amniocentesis 
choice appears to be inconsistent with the first two of the above life cycle patterns observed in 
the data for amniocenteses, although it does tend to characterize the third one. In the following 
section, we consider the life cycle patterns that are generated by more complicated versions of 
our dynamic model, examining how the model’s predictions concerning life cycle variation in 
the likelihood of having an amniocentesis change as we vary the rate of discounting, the utility 
costs of abortions and miscarriages and with age-variation in the rates of genetic disorders, such 
                                                                                                                                                             
and 40.3% respectively of this population respectively. 85.6% of this population is married. Figure 7 is constructed 
through regression adjustments and then equation (25) is applied. In future versions of this paper these will be 
constructed entirely non-parametrically.   22
as displayed in Figure 1. We contrast these predictions with those generated by a myopic model 
of amniocentesis choice, exploiting the fact that such a model arises as a special case of our 
dynamic model under the case where the future is completely discounted (i.e.,  = 0.0) when 
women (couples) make their childbearing and amniocentesis decisions. 
4.  Varying Features of the Model and Tracking the Observed Dynamic 
Patterns of Amniocentesis Choice 
  In this section, we examine how changes in the various features of our dynamic model of 
amniocentesis choice affect our ability to “replicate” the age patterns found in the data on the 
incidence of amniocenteses described in the preceding section. We pay particular attention to 
contrasting our dynamic model with the special case in which women are myopic with respect to 
these choices, i.e., do not take full account of the future in making their choices. In this 
exploration, our goal is not to fit our model to data in a statistical sense. Rather, our goal is to see 
whether our model, and its underlying features, is rich enough to characterize the dynamic 
patterns of amniocentesis choice outlined above. We proceed by plugging in values for the key 
parameters (or rates) for the model in Section 2 in an attempt to “calibrate” the model, assessing 
how well we mimic the dynamic patterns of amniocentesis choice at different ages by plotting 
how the critical value, 
*
t  , for  1
D   varies with age.
14 To simplify our analysis, we normalize the 
value of a (chromosomally) healthy child to one ( 1
N   = 1), and specify the following parameters 
of the model to be age-invariant and equal to the following values: annual pregnancy rate (p) to 
0.3 and the rate of procedure-induced miscarriage (m) to 0.0067 (1/150). We then explore how 
varying the following parameters affects 
*
t   and thus the incidence of amniocenteses with age: 
                                                 




t    in decision-rule (21), where 
1
D   is treated as a random variable with a known distribution.   23
(i) the discount rate (); (ii) the utility cost of an abortion (); (iii) the utility cost of a 
miscarriage (); and (iv) the rate of genetic disorders (Down syndrome) (q), where for the latter 
parameter we consider specifications in which q is assumed to be age-invariant and to vary with 
age as in Figure 1.
15 
  The results of this exploration of our model are displayed in Figures 8 through 12. 
Consider first the role that discounting plays in affecting the dynamic pattern of 
*  , and, thus, 
the incidence of amniocenteses. Figure 8 displays how 
*   varies with age assuming that the rate 
of genetic disorders associated with births is age-invariant (i.e., qa = q for all a) and there are 
zero (utility) costs of abortions and miscarriages (i.e.,  =  = 0). Consider first the values for 
*   
when  = 0.0, i.e., the “myopic” model. In our characterization of the myopic model, a woman is 
assumed to not take account of the possibility of “replacing” a current pregnancy with a future 
pregnancy in her decision to get amniocentesis because she completely ignores the future. 
However, we do assume that a woman takes account of the “durable” nature of children and of 
abortion and miscarriage costs in making her childbearing, amniocentesis and abortion decisions, 
via the “payoff values” 
D  ,  and . That is, we assume that women still take account of the 
PDU she receives from her child and the PDU associated with any abortion or miscarriage she 
experiences.  
Figure 8 here 
  As can be seen in Figure 8, the value for 
*   at early ages increases—and thus the 
                                                 
15 An annual rate of pregnancy of 0.3 is consistent with data from the Hutterites. The average number of births to 
fecund women in this population is approximately 11. In our simulations, we use this age-invariant rate, despite 
clear evidence that pregnancy rates tend to fall over time (see, for example, Leridon, 2008). Allowing for a 
monotonically declining pregnancy rate with maternal age would tend to exacerbate the life-cycle effect, i.e. as 
women approach menopause without having reached the desired family size, the disutility from an amniocentesis-
induced miscarriage would be greater as the probability of becoming pregnant again would be declining over time.    24
probability of having an amniocentesis increases, as we move from the myopic version of the 
model to the two variants of the Dynamic Model ( = 0.50 and  = 0.95). This increase reflects 
the “option value” of knowing about the genetic status of a fetus at early ages. When, in the 
Dynamic Model, the future is taken into account in decision-making, forward looking women 
have an incentive to learn about the genetic status of a fetus precisely because they realize that 
they have the option of aborting such a fetus if the amniocentesis is positive and replacing that 
fetus in the future. Women under the Myopic Model do not consider this option and, thus, have 
no greater incentive to have an amniocentesis at early ages than they do at older ages. Note, too, 
that the less a woman discounts the future—i.e., comparing the results for  = 0.95 with those for 
 = 0.50—the greater is this incentive to have an amniocentesis at early ages. Finally, as women 
age, there is no change in the value of 
*   under the Myopic model, but this critical value 
declines with age under either specification of the Dynamic Model. Furthermore, 
*   converges 
to the same value under all three specifications at age T, the end of the woman’s reproductive 
life. This convergence follows from the fact that the decision rule at age T is identical under both 
the Dynamic and Myopic model, since there is no future at that age.  
  In addition, this decline in 
*   with age under the Dynamic specification reflects another 
force within our model. As noted above, the higher the  1
D   (and  1
N  ), the greater the desire of 
women to have a child, even if it is one that has Down syndrome. As women approach the end of 
their reproductive careers, their incentive to have a child increases under the Dynamic 
specification. As a result, childless women have an incentive to avoid actions that further 
postpone births. This includes undergoing an amniocentesis, since the latter procedure is 
assumed to increase the likelihood that a woman experiences a miscarriage. Thus, as one 
approaches T, forward-looking women will have less incentive to undergo an amniocentesis in   25
order to reduce the risk of a miscarriage, which would further postpone their chances of having a 
birth prior to menopause. Note, that this age-dependent incentive is not present in the Myopic 
model, precisely because it does not have women (couples) be forward looking when making 
their choices over the life cycle. 
  In Figure 9, the only change in the specifications of either the Dynamic or Myopic 
models is to allow the probability of a genetic disorder to vary with age, following the pattern in 
Figure 1. Several interesting implications emerge by comparing the age patterns for 
*   displayed 
in this Figure 8 and Figure 9. First, both figures make clear that forward-looking women have a 
greater incentive to have an amniocentesis at early ages compared to optimal choices under the 
Myopic Model. Second, when women face a rising (with age) risk of having a child having a 
genetic disorder, under either the Dynamic or Myopic model, their incentive to have an 
amniocentesis is lowered at early ages. In the Myopic model, the rising pattern to 
*   simply 
reflects a age-by-age response to the increasing risk of a birth defect with age; as the risk of a 
birth defect goes up, the incentives to learn about the potential problems with a fetus rise. With 
respect to the Dynamic models, the consequences of rising rates of birth defects for the age 
pattern in 
*   depend on the extent of discounting. At the extreme, if women do not discount the 
future at all, i.e.,  = 1.00, the likelihood of an amniocentesis does not rise with age. Rather, the 
option value effect noted above dominates her (their) amniocentesis decisions, giving rise to high 
rates of amniocentesis at early ages, while the risks of miscarriage associated with an 
amniocentesis, causes their utilization to decline as the woman (couple) reaches the end of the 
childbearing period.  
Figure 9 here 
  In Figures 10 and 11, we examine how the predictions of our Myopic and Dynamic   26
models, respectively, are affected by changes in the utility costs of abortions and costs. As can be 
seen from these figures, higher costs to either abortion reduces the critical value for 
amniocenteses equally at all ages while higher costs for miscarriages tend to reduce the incidence 
of amniocenteses more at younger ages than at older ones.  
Figure 10 here 
Figure 11 here 
  Finally, in Figure 12, we summarize our findings by graphing the life cycle pattern of 
*   
for both our Dynamic and Myopic models, for both age-invariant and age-varying rates of 
genetic disorders (1-q). While more work needs to be done in “calibrating” the Dynamic 
models,
16 this figure suggests that a Dynamic model in which there is some, but not complete, 
discounting of the future and which incorporates the age-varying rates of birth defects (1-q) 
displayed in Figure 1 can generate the qualitative features of the observed age-patterns in the 
incidence of amniocenteses. In particular, such a model is able to generate both the rise in the 
incidence of amniocentesis with age and the decline in its utilization at older ages. In contrast, 
the Myopic model we calibrate does not generate a decline in 
*
Ts    – and, thus, in the incidence 
of amniocenteses – as women approach menopause.  
Figure 12 here 
5.  Concluding Observations 
In this paper, we examine the appropriateness of the threshold-age approach in the 
protocol for recommending amniocentesis testing to pregnant women, based on a dynamic model 
of the decision making process. In particular, we consider the potentially welfare enhancing 
                                                 
16 In particular, it would appear that we can achieve age-patterns that more closely accord with those in the actual 
data for amniocenteses displayed in Figures 5 through 7 by increasing some combination of the disutility costs of 
miscarriages or abortions.   27
effect of fully informing women of the risks and benefits of such a procedure, irrespective of age. 
  Based on our calibration exercise, it does appear that the features of our model may be 
important in accounting for the observed life cycle pattern of amniocenteses. In particular, the 
dynamic model of optimal amniocentesis choice outlined above, when it includes some, but not 
total, discounting of the future and conditions on increasing rates of genetic disorders with age, 
does appear to generate age-patterns consistent with the data. Moreover, it appears that Myopic 
models fail to predict the decline in the incidence of amniocentesis with age that are found in the 
data. While further exploration of the calibration of the Dynamic model is needed (for instance, 
to account for endogenous desired family size or an age-dependent pregnancy rate) these initial 
findings suggest real merit to develop and estimate a dynamic structural model of amniocentesis 
choice of the sort outlined in this paper.  
  These initial findings, if they hold up to further scrutiny, have potentially important 
implications for medical practice and insurance company policies for the funding of this 
procedure. In particular, our results suggest that the medical community and insurance 
companies may be ignoring the option value of amniocenteses when women are young. 
Currently, 80% of Down syndrome children are born to women under the age of 35. Our model 
suggests that some of these young women, if informed of the full costs and benefits of the 
procedure and given the option to have it, would undergo an amniocentesis and, upon learning of 
the results of this test, would choose to abort a chromosomally abnormal fetus in favor of a 
future pregnancy that could result in a healthy birth. As such, existing guidelines of health care 
providers and insurance companies in setting policies for the ages at which amniocenteses will 
be funded are potentially inconsistent with the choices some women would make for themselves 
if free to acquire the information provided by this procedure. Further exploration and estimation   28
of this model may help to inform medical practice and policy by explicitly accounting for choice 
behavior among women (couples) that take account of the future consequences of their actions. 
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Fig. 1. Number of Chromosomally Abnormal Fetuses per 100,000 Pregnancies 
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Fig. 2. Decision tree for general model at (mother’s) age t 
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Fig. 5. Percent of estimated wanted and viable pregnancies that undergo amniocentesis, All mothers 
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Fig. 6. Percent of wanted and viable pregnancies that undergo amniocentesis, Mothers with yrs. of school  12 
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Fig. 7. Percent of wanted and viable pregnancies that undergo amniocentesis, Regression Adjusted 































β= 0.95, Constant (1-q)
Region below a given graph: Choose Amnio
Region above a given graph: Choose ~Amnio
Dynamic Model
β= 0.50, Constant (1-q)
Myopic Model
β= 0.00, Constant (1-q)
 
 
Fig. 8. Simulations for alternative models with age-invariant probability of Down syndrome (1-q) 






























Region below a given graph: Choose Amnio
Region above a given graph: Choose ~Amnio
Dynamic Model
β= 1.00, Age-Varying (1-q)
Dynamic Model
β= 0.95, Age-Varying (1-q)
Dynamic Model
β= 0.50, Age-Varying (1-q)
Myopic Model
β= 0.00, Age-Varying (1-q)
 
 
Fig. 9. Simulations for alternative models with age-varying probability of Down syndrome (1-q) 






























Region below a given graph: Choose Amnio
Region above a given graph: Choose ~Amnio
α = -0.2, μ = 0
α = -0.2, μ = -0.132 α = 0, μ = 0
 
 
Fig. 10. Simulations of Myopic model with alternative costs of abortion () and miscarriage () 






























Region below a given graph: Choose Amnio
Region above a given graph: Choose ~Amnio
α = -0.2, μ = 0
α = -0.2, μ = -0.132
α = 0, μ = 0
 
 
Fig. 11. Simulations of Dynamic model with alternative costs of abortion () and miscarriage () 






























Region below a given graph: Choose Amnio
Region above a given graph: Choose ~Amnio
Myopic Model
β= 0.00, Constant (1-q)
Myopic Model
β= 0.00, Age-Varying (1-q)
Dynamic Model
β= 0.95, Age-Varying (1-q)
Dynamic Model
β= 0.95, Constant (1-q)
 
 
Fig. 12. Simulations of Dynamic and Myopic models for alternative discount rates () and probabilities of Down syndrome (1-q) 
[Other assumptions: Prob. of pregnancy (p) = 0.3; Prob. of procedure-induced miscarriage (m) =0.0067; No costs of abortion (=0) or miscarriage (=0)] 
 